Fun Pharma Images

Collection by PharmaGuy

281 
Pins
 • 
602 
Followers

These are some images I created to help illustrate posts to Pharma Marketing Blog and articles in Pharma Marketing News. Follow the links to get the story behind the image!

PharmaGuy
Home of Bizarro by Dan Piraro, a single-panel comic strip making people laugh for over 30 years. Haha Funny, You Funny, Funny Art, Funny Things, Funny Stuff, Pharmacy Humor, Medical Humor, Adult Cartoons, Funny Cartoons

Bizarro

Home of Bizarro by Dan Piraro, a single-panel comic strip making people laugh for over 30 years.

Media preview New Market, Fitbit, Fun, Lol, Funny

TweetDeck

TweetDeck is your personal browser for staying in touch with what’s happening now.

“We Want the Gold” Standard of FDA Approval, Says PhRMA CEO Ubl Trump Immigration, On The Issues, The Agency, New Market, Inspirational Videos, Encouragement, Positivity, Sayings, Reading

“We Want the Gold” Standard of FDA Approval, Says PhRMA CEO Ubl | Pharma Industry Regulation

The CEO of the Pharmaceutical Research and Manufacturers of America on Tuesday came out strongly in favor of a rigorous Food and Drug Administration. His remarks come as the Trump administration weighs potential candidates to lead the agency who have suggested they would radically change how it vets new drugs. Asked by STAT about the notion that the FDA should no longer evaluate drugs for effectiveness, the industry trade group’s Stephen Ubl was unambiguous: “We believe that the FDA review…

Media Tweets by Pharma Guy (@pharmaguy) | Twitter New Market, Health Care, How To Get, Marketing, Thoughts, Guys, Twitter, Boyfriends, Boys

Media Tweets by Pharma Guy (@pharmaguy)

The latest media Tweets from Pharma Guy (@pharmaguy). Supporters of the #Pharma & #Healthcare #Marketing Ecosystem. #Marketers, #Speakers, #Bloggers & #ThoughtLeaders welcome. http://pharma-mkting.com. Ewing, NJ

Trump Freezes FDA & Puts Century Cures in Jeopardy New Program, The Agency, Military Personnel, A Decade, 21st Century, The Cure, How To Apply, Politics, Medical

Trump Freezes FDA & Puts 21st Century Cures in Jeopardy | Pharma Industry Regulation

A federal hiring freeze could put FDA in a vise, squeezed between complying with obligations to implement new programs created by the 21st Century Cures Act and meeting user fee goals for medical product reviews. The 21st Century Cures Act authorizes $500 million over a decade for FDA to implement the law. Most of the money is allocated to hiring new staff. A day after President Trump ordered a short-term federal hiring freeze and demanded a long-term plan to downsize the federal government…

Trump's Comments Are Big Pharma's Nightmare Trump Comments, Republican Party, Good Company, Drugs, Insight, It Hurts, Shit Happens, Marketing, News

Trump's Comments Are Big Pharma's Nightmare | Pharmaguy's Insights Into Drug Industry News

The drug industry is just wrapping up what looked like an upbeat week here at the J.P. Morgan Healthcare Conference in San Francisco, where all of the healthcare industry's biggest executives come every year to court investors and negotiate deals. This is the where big mergers are conceived. But now every pharma and biotech executive has a lump in his throat (they're mostly men). Because of Donald Trump.Many pharmaceutical executives hoped that because of the Republican Party's long-term…

Pharma Guy (@pharmaguy) | Twitter New Market, Health Care, Marketing, Guys, Twitter, Image, Boyfriends, Boys, Men

Pharma Guy (@pharmaguy)

The latest Tweets from Pharma Guy (@pharmaguy). Supporters of the #Pharma & #Healthcare #Marketing Ecosystem. #Marketers, #Speakers, #Bloggers & #ThoughtLeaders welcome. https://t.co/N1Jf9eQBXf. Ewing, NJ

Valeant Looks to Revive Xifaxan with "Bubble Guts the Sales Rep." Will It Work? Primary Care Physician, Crohns, How To Get, How To Plan, Drugs, Insight, Meant To Be, Bubbles, Sayings

Valeant Looks to Revive Xifaxan with "Bubble Guts the Sales Rep." Will It Work? | Pharmaguy's Insights Into Drug Industry News

Now that Valeant’s $10 billion talks to sell its Salix unit to Takeda have reportedly fallen through, the company is taking matters into its own hands with a “significant” GI sales force expansion. But whether that expansion can help get its lagging meds going remains to be seen. The plan? Rev up growth in the underperforming GI business by adding reps who will focus on potential primary care physician prescribers of IBS-D med Xifaxan and oral opioid-induced constipation med Relistor…

Allowing Pharma Sales Reps to Discuss Off-Label Drug Use Would Make Them More Helpful, Says KevinMD Im Useless, American Heart Association, Cardiology, How To Get, How To Plan, Drugs, Insight, Meant To Be, Literature

Allowing Pharma Sales Reps to Discuss Off-Label Drug Use Would Make Them More Helpful, Says KevinMD | Pharmaguy's Insights Into Drug Industry News

In the past, pharma reps were a source of samples that I could provide to my poorer patients who could not afford their meds. This was a real value: I depended on reps to provide these medications for my patients. In the days of print-only access to journals, I may not have been as current with the medical literature. Reps would often come in and discuss breaking trial news that I had not yet had time to read about. Often they would discuss upcoming trials and plans for the future. We would…

Doctors Urged to Forget Conversation with Parents About HPV Vaccination and Just “Announce” It’s Time To Do It! Adolescence, Pediatrics, Doctors, Clinic, Conversation, Drugs, Insight, Parents, Medicine

Doctors Urged to Forget Conversation with Parents About HPV Vaccination and Just “Announce” It’s Time To Do It! | Pharmaguy's Insights Into Drug Industry News

OBJECTIVE: Improving provider recommendations is critical to addressing low human papillomavirus (HPV) vaccination coverage. Thus, we sought to determine the effectiveness of training providers to improve their recommendations using either presumptive “announcements” or participatory “conversations.” METHODS: In 2015, we conducted a parallel-group randomized clinical trial with 30 pediatric and family medicine clinics in central North Carolina. We randomized clinics to receive no training…

Think Califf's Job is Safe? History & Trump's Promises Would Suggest Otherwise George Hw, Resignation Letter, American Heart Association, Democratic Presidential Candidates, New President, The Agency, Donald Trump, History, Fun

Think Califf's Job is Safe? History & Trump's Promises Would Suggest Otherwise | Pharma Industry Regulation

A litmus test of President-elect Donald Trump's plans for the FDA will come when the agency's commissioner, Dr. Robert Califf, hands in his resignation letter in the coming weeks. It is standard procedure for the head of the FDA to offer to resign after a change in administration, and the new president may or may not accept. How Trump responds to Califf's letter could be an indicator of his plans for the FDA, having pledged reforms such as making it easier to import medicines made outside…

Pharma Guy (@pharmaguy) | Twitter Fractions, Health Care, How To Get, Marketing, Thoughts, Guys, Twitter, Blog, Image

Pharma Guy (@pharmaguy)

The latest Tweets from Pharma Guy (@pharmaguy). Supporters of the #Pharma & #Healthcare #Marketing Ecosystem. #Marketers, #Speakers, #Bloggers & #ThoughtLeaders welcome. https://t.co/N1Jf9eQBXf. Ewing, NJ

Will Survive Under President Trump? National Review, Presidents, Survival, Fun, Lol, Funny

Will #FDA Survive Under President Trump? | Pharma Industry Regulation

It’s been less than a year since Robert Califf was sworn in as the Food and Drug Administration’s chief, but already the agency is facing post-election upheaval. Public health advocates are bracing for a seismic shift: a surrender of the agency’s rules for off-label promotion of drugs; the importation of more drugs from other countries; and fewer requirements for clinical trials — long the gold standard for determining whether medicines are safe and effective. “Between a Trump presidency and…

Isis Finally Changes Its Unfortunate Name to Avoid Confusion with Terrorists! Paris Attack, Isis Goddess, Confusion, Drugs, Insight, Names, Change, Fun, Lol

Isis #Pharma Finally Changes Its Unfortunate Name to Avoid Confusion with Terrorists! | Pharmaguy's Insights Into Drug Industry News

After deliberating for most of the year, Isis Pharmaceuticals Inc said on Friday it would change its name to avoid being confused with the Islamist militant group known as ISIS. The drugmaker – named after the Egyptian protector and healer goddess Isis, who was revered as a protector and healer – has been around for more than a quarter century. The Carlsbad, California-based company’s stock dropped about 4% on the first trading day after the Paris attacks, for which ISIS claimed…

OMG!+Drug+Side+Effects+(Almost)+Killed+Granny!+ER+Study+Shows Side Effects, Drugs, Insight, Study, Fun, Studio, Studying, Research, Lol

OMG! Drug Side Effects (Almost) Killed Granny! ER Study Shows | Pharmaguy's Insights Into Drug Industry News

The study has a lot of interesting information, and here are some highlights: Side effects from medication are causing more older Americans to visit emergency rooms and leading to more hospitalizations, according to an analysis of ER data from 2005-2006 and 2013-2014. And across all age groups, the drugs most often causing side effects that sent people to an ER were the same ones identified a decade ago —anticoagulants, antibiotics, diabetes agents, and opioid analgesics. These were among…

Will FDA Open a Path to Off-Label Promotion from Pharma to Payers & Not Patients or Providers? Regulatory Affairs, Medical Information, Product Label, Clinic, Promotion, Health Care, Fun, Lol, Funny

Will FDA Open a Path to Off-Label Promotion from Pharma to Payers & Not Patients or Providers? | Pharma Industry Regulation

Drugmakers told the FDA that allowing them to share off-label information with payers would be a critical first step in redefining off-label regulations. The FDA held a two-day public hearing this week (see http://sco.lt/7UY48X) to gather information about off-label communications, after a series of lawsuits were decided in favor of the pharmaceutical industry. At the hearing, industry stakeholders agreed with concerns over supplying information not vetted by the FDA to consumers, who may…